Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms

Biological Psychiatry

Volumn 75, Issue 6, 2014, Pages 470-478

  Bloomfield, Michael A P ^a,c   Morgan, Celia J A ^b   Egerton, Alice ^a,c   Kapur, Shitij ^c   Curran, H Valerie ^b   Howes, Oliver D ^a,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Addiction; dependence; dopamine; drugs; imaging; psychosis

Indexed keywords

6 FLUORODOPA F 18; CANNABIS; DOPA; DOPAMINE;

ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CANNABIS ADDICTION; CASE CONTROL STUDY; CORPUS STRIATUM; DIAGNOSTIC USE; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; FEMALE; FUNCTIONAL NEUROIMAGING; HUMAN; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; SCINTISCANNING; YOUNG ADULT;

CANNABIS; CASE-CONTROL STUDIES; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MARIJUANA ABUSE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOSES, SUBSTANCE-INDUCED; YOUNG ADULT;

EID: 84894479797     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.05.027     Document Type: Article

References (92)

1. United Nations Office on Drugs & Crime World Drug Report 2010 United Nations Publications New York
2. J.C. Anthony, L. Warner, and R. Kessler Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from the National Comorbidity Survey Exp Clin Psychopharmacol 2 1994 244 268
3. J.-J. Moreau Du Haschisch et de l'alienation mentale 1845 Masson Paris
4. D.C. D'Souza, E. Perry, L. MacDougall, Y. Ammerman, T. Cooper, and Y.T. Wu et al. The psychotomimetic effects of intravenous delta-9- tetrahydrocannabinol in healthy individuals: Implications for psychosis Neuropsychopharmacology 29 2004 1558 1572
5. T.H. Moore, S. Zammit, A. Lingford-Hughes, T.R. Barnes, P.B. Jones, and M. Burke et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review Lancet 370 2007 319 328
6. M. Di Forti, C. Morgan, P. Dazzan, C. Pariante, V. Mondelli, and T.R. Marques et al. High-potency cannabis and the risk of psychosis Br J Psychiatry 195 2009 488 491
7. N.D. Volkow, G.J. Wang, J.S. Fowler, D. Tomasi, and F. Telang Addiction: Beyond dopamine reward circuitry Proc Natl Acad Sci U S A 108 2011 15037 15042
8. A. Heinz, T. Siessmeier, J. Wrase, H.G. Buchholz, G. Gründer, and Y. Kumakura et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: A combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients Am J Psychiatry 162 2005 1515 1520
9. J.C. Wu, K. Bell, A. Najafi, C. Widmark, D. Keator, and C. Tang et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal Neuropsychopharmacology 17 1997 402 409
10. D. Martinez, K.M. Carpenter, F. Liu, M. Slifstein, A. Broft, and A.C. Friedman et al. Imaging dopamine transmission in cocaine dependence: Link between neurochemistry and response to treatment Am J Psychiatry 168 2011 634 641
11. G.J. Wang, L. Smith, N.D. Volkow, F. Telang, J. Logan, and D. Tomasi et al. Decreased dopamine activity predicts relapse in methamphetamine abusers Mol Psychiatry 17 2012 918 925
12. O.D. Howes, and S. Kapur The dopamine hypothesis of schizophrenia: Version III - the final common pathway Schizophr Bull 35 2009 549 562
13. M. Laruelle The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies Res Brain Res Rev 31 2000 371 384
14. O.D. Howes, A.J. Montgomery, M.C. Asselin, R.M. Murray, P.M. Grasby, and P.K. McGuire Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis Br J Psychiatry Suppl 51 2007 S13 S18
15. O.D. Howes, P. Fusar-Poli, M. Bloomfield, S. Selvaraj, and P. McGuire From the prodrome to chronic schizophrenia: The neurobiology underlying psychotic symptoms and cognitive impairments Curr Pharm Des 18 2012 459 465
16. E.M. Meisenzahl, G.J. Schmitt, J. Scheuerecker, and H.J. Möller The role of dopamine for the pathophysiology of schizophrenia Int Rev Psychiatry 19 2007 337 345
17. D.J. Lodge, and A.A. Grace Developmental pathology, dopamine, stress and schizophrenia Int J Dev Neurosci 29 2011 207 313
18. O.D. Howes, A. Egerton, V. Allan, P. McGuire, P. Stokes, and S. Kapur Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging Curr Pharm Des 15 2009 2550 2559
19. S.K. Bose, F.E. Turkheimer, O.D. Howes, M.A. Mehta, R. Cunliffe, P.R. Stokes, and P.M. Grasby Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging Schizophr Res 106 2008 148 155
20. M. Laruelle, A. Abi-Dargham, R. Gil, L. Kegeles, and R. Innis Increased dopamine transmission in schizophrenia: Relationship to illness phases Biol Psychiatry 46 1999 56 72
21. G.J. Lyon, A. Abi-Dargham, H. Moore, J.A. Lieberman, J.A. Javitch, and D. Sulzer Presynaptic regulation of dopamine transmission in schizophrenia Schizophr Bull 37 2011 108 117
22. O.D. Howes, J. Kambeitz, E. Kim, D. Stahl, M. Slifstein, and A. Abi-Dargham et al. The Nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies Arch Gen Psychiatry 69 2012 776 786
23. J. Hietala, E. Syvälahti, K. Vuorio, V. Räkköläinen, J. Bergman, and M. Haaparanta et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients Lancet 346 1995 1130 1131
24. J. Reith, C. Benkelfat, A. Sherwin, Y. Yasuhara, H. Kuwabara, and F. Andermann et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis Proc Natl Acad Sci U S A 91 1994 11651 11654
25. M.H. Dao-Castellana, M.L. Paillère-Martinot, P. Hantraye, D. Attar-Lévy, P. Rémy, and C. Crouzel et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients Schizophr Res 23 1997 167 174
26. A. Breier, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, and A. de Bartolomeis et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method Proc Natl Acad Sci U S A 94 1997 2569 2574
27. G.G. Wallis, J.F. McHarg, and O.C. Scott Acute psychosis caused by dextro-amphetamine Br Med J 17 1949 1394
28. J.A. Lieberman, J.M. Kane, and J. Alvir Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology (Berl) 91 1987 415 433
29. O.D. Howes, A.J. Montgomery, M.C. Asselin, R.M. Murray, I. Valli, and P. Tabraham et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia Arch Gen Psychiatry 66 2009 13 20
30. O.D. Howes, S.K. Bose, F. Turkheimer, I. Valli, A. Egerton, and L.R. Valmaggia et al. Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study Am J Psychiatry 168 2011 1311 1317
31. O. Howes, S. Bose, F. Turkheimer, I. Valli, A. Egerton, and D. Stahl et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study Mol Psychiatry 16 2011 885 886
32. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, et al. (2013): presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort [published online ahead of print January 8]. Biol Psychiatry.
33. M.B. Bowers, and J.T. Kantrowitz Elevated plasma dopamine metabolites in cannabis psychosis Am J Psychiatry 164 2007 1615 1616
34. L.N. Voruganti, P. Slomka, P. Zabel, A. Mattar, and A.G. Awad Cannabis induced dopamine release: An in-vivo SPECT study Psychiatry Res 107 2001 173 177
35. S.R. Wachtel, M.A. ElSohly, S.A. Ross, J. Ambre, and H. de Wit Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans Psychopharmacology (Berl) 161 2002 331 339
36. E.D. French Delta9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors Neurosci Lett 226 1997 159 162
37. S.P. Banerjee, S.H. Snyder, and R. Mechoulam Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes J Pharmacol Exp Ther 194 1975 74 81
38. B. Bosier, G.G. Muccioli, B. Mertens, S. Sarre, Y. Michotte, and D.M. Lambert et al. Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo Neuropharmacology 62 2012 2328 2336
39. J.M. Ng Cheong Ton, G.A. Gerhardt, M. Friedemann, A.M. Etgen, G.M. Rose, and N.S. Sharpless et al. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: An in vivo electrochemical and in vivo microdialysis study Brain Res 451 1988 59 68
40. M. Navarro, J.J. Fernández-Ruiz, R. de Miguel, M.L. Hernández, M. Cebeira, and J.A. Ramos An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity Behav Brain Res 57 1993 37 46
41. J.F. Cheer, K.M. Wassum, M.L. Heien, P.E. Phillips, and R.M. Wightman Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats J Neurosci 24 2004 4393 4400
42. M.A. Gorriti, F. Rodríguez de Fonseca, M. Navarro, and T. Palomo Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats Eur J Pharmacol 365 1999 133 142
43. N.B. Urban, M. Slifstein, J.L. Thompson, X. Xu, R.R. Girgis, and S. Raheja et al. Dopamine release in chronic cannabis users: A [(11)C]raclopride positron emission tomography study Biol Psychiatry 71 2012 677 683
44. S. Sevy, G.S. Smith, Y. Ma, V. Dhawan, T. Chaly, and P.B. Kingsley et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography Psychopharmacology (Berl) 197 2008 549 556
45. P.R. Stokes, A. Egerton, B. Watson, A. Reid, J. Lappin, and O.D. Howes et al. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability J Psychopharmacol 26 2012 144 149
46. N.D. Volkow, G.J. Wang, J.S. Fowler, J. Logan, S.J. Gatley, and R.R. MacGregor et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics Alcohol Clin Exp Res 20 1996 1594 1598
47. C. Leroy, L. Karila, J. Martinot, M. Lukasiewicz, E. Duchesnay, and C. Comtat et al. Striatal and extrastiatal dopamine transporter in cannabis and tobacco addiction: A high-resolution PET study Addict Biol 17 2011 981 990
48. M. Arendt, R. Rosenberg, L. Foldager, G. Perto, and P. Munk-Jørgensen Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases Br J Psychiatry 187 2005 510 515
49. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W. Williams Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996 American Psychiatric Press Washington, DC
50. NIMH Genetics Initiative Family Interview for Genetic Studies(FIGS) 1992 National Institute of Mental Health Rockville, MD
51. L.J. Phillips, A.R. Yung, and P.D. McGorry Identification of young people at risk of psychosis: Validation of Personal Assessment and Crisis Evaluation Clinic intake criteria Aust N Z J Psychiatry 34 2000 S164 S169
52. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision (DSM-IVTR) 2005 American Psychiatric Association Washington, DC
53. E.J. Barkus, J. Stirling, R.S. Hopkins, and S. Lewis Cannabis-induced psychosis-like experiences are associated with high schizotypy Psychopathology 39 2006 175 178
54. I.H. Akinci, R.E. Tarter, and L. Kirisci Concordance between verbal report and urine screen of recent marijuana use in adolescents Addict Behav 26 2001 613 619
55. C.J.A. Morgan, C. Gardener, G. Schafer, S. Swan, C. Demarchi, and T.P. Freeman et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being Psychol Med 42 2012 391 400
56. O.J. Mason, C.J. Morgan, A. Stefanovic, and H.V. Curran The Psychotomimetic States Inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis Schizophr Res 103 2008 138 142
57. K. Smith, and J., Flatley Drug Misuse Declared: Findings from the 2010/11 British Crime Survey (England and Wales) 2011 Office of National Statistics, Home Office London
58. 18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease Neurology 44 1994 1292 1297
59. P. Cumming, G.C. Léger, H. Kuwabara, and A. Gjedde Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans J Cereb Blood Flow Metab 13 1993 668 675
60. M. Guttman, G. Léger, A. Reches, A. Evans, H. Kuwabara, J.M. Cedarbaum, and A. Gjedde Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa Mov Disord 8 1993 298 304
61. F.E. Turkheimer, M. Brett, D. Visvikis, and V.J. Cunningham Multiresolution analysis of emission tomography images in the wavelet domain J Cereb Blood Flow Metab 19 1999 1189 1208
62. C. Studholme, D.L. Hill, and D.J. Hawkes Automated 3-D registration of MR and CT images of the head Med Image Anal 1 1996 163 175
63. D. Martinez, M. Slifstein, A. Broft, O. Mawlawi, D.R. Hwang, and Y. Huang et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum J Cereb Blood Flow Metab 23 2003 285 300
64. A. Egerton, A. Demjaha, P. McGuire, M.A. Mehta, and O.D. Howes The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function Neuroimage 50 2010 524 531
65. P. Hartvig, S.M. Aquilonius, J. Tedroff, L. Reibring, H. Agren, and P. Bjurling et al. Positron emission tomography of L-dopa utilization in the brains of rhesus monkeys and human volunteers Acta Radiol Suppl 376 1991 149 150
66. P. Hartvig, R. Torstenson, J. Tedroff, Y. Watanabe, K.J. Fasth, and P. Bjurling et al. Amphetamine effects on dopamine release and synthesis rate studied in the rhesus monkey brain by positron emission tomography Neural Transm 104 1997 329 339
67. H. Hoshi, H. Kuwabara, G. Léger, P. Cumming, M. Guttman, and A. Gjedde 6-[18F]fluoro-L-dopa metabolism in living human brain: A comparison of six analytical methods J Cereb Blood Flow Metab 13 1993 57 69
68. C.S. Patlak, and R.G. Blasberg Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab 5 1985 584 590
69. F.E. Turkheimer, J.A. Aston, M.C. Asselin, and R. Hinz Multi-resolution Bayesian regression in PET dynamic studies using wavelets Neuroimage 32 2006 111 121
70. D.S. Albrecht, P.D. Skosnik, J.M. Vollmer, M.S. Brumbaugh, K.M. Perry, and B.H. Mock et al. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users Drug Alcohol Depend 128 2012 52 57
71. A.S. Bloom Effect of delta9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes J Pharmacol Exp Ther 221 1982 97 103
72. D.E. Walters, and L.A. Carr Perinatal exposure to cannabinoids alters neurochemical development in rat brain Pharmacol Biochem Behav 29 1988 213 216
73. X. Wu, and E.D. French Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: An electrophysiological assessment Neuropharmacology 39 2000 391 398
74. 2/3 receptors in the mesoaccumbens and nigrostriatal systems Neuropsychopharmacology 37 2012 2355 2367
75. A.T. Behan, M. Hryniewiecka, C.M. O'Tuathaigh, A. Kinsella, M. Cannon, and M. Karayiorgou et al. Chronic adolescent exposure to delta-9- tetrahydrocannabinol in COMT mutant mice: Impact on indices of dopaminergic, endocannabinoid and GABAergic pathways Neuropsychopharmacology 37 2012 1773 1783
76. H.H. van Hell, M. Vink, L. Ossewaarde, G. Jager, R.S. Kahn, and N.F. Ramsey Chronic effects of cannabis use on the human reward system: an fMRI study Eur Neuropsychopharmacol 20 2010 153 163
77. M.A. Nader, D. Morgan, H.D. Gage, S.H. Nader, T.L. Calhoun, and N. Buchheimer et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys Nat Neurosci 9 2006 1050 1056
78. L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine Behav Brain Res 84 1997 259 268
79. B.Y. Glenthoj, T. Mackeprang, C. Svarer, H. Rasmussen, L.H. Pinborg, and L. Friberg et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender Biol Psychiatry 60 2006 621 629
80. J. Hirvonen, R.S. Goodwin, C.T. Li, G.E. Terry, S.S. Zoghbi, and C. Morse et al. Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers Mol Psychiatry 17 2012 642 649
81. J.L. Thompson, N. Urban, M. Slifstein, X. Xu, L.S. Kegeles, and R.R. Girgis et al. Striatal dopamine release in schizophrenia comorbid with substance dependence [published online ahead of print August 7] Mol Psychiatry. 2012
82. J.M. Littleton, K.I. Maclean, and G. Brownlee Proceedings: Alterations in dopamine uptake in rat corpus striatum induced by combinations of stress and delta8-tetrahydrocannabinol (delta8-THC) Br J Pharmacol 56 1976 370P
83. M. Ashtari, K. Cervellione, J. Cottone, B.A. Ardekani, S. Sew, and S. Kumra Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use J Psychiatr Res 43 2009 189 204
84. M.G. Bossong, B.N. van Berckel, R. Boellaard, L. Zuurman, R.C. Schuit, and A.D. Windhorst et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum Neuropsychopharmacology 34 2009 759 766
85. P.R. Stokes, M.A. Mehta, H.V. Curran, G. Breen, and P.M. Grasby Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48 2009 186 190
86. E. Barkus, P.D. Morrison, D. Vuletic, J.C. Dickson, P.J. Ell, and L.S. Pilowsky et al. Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study J Psychopharmacol 25 2011 1462 1468
87. M.O. Maykut Health consequences of acute and chronic marihuana use Prog Neuropsychopharmacol Biol Psychiatry 9 1985 209 238
88. G.A. Miller, and J.P. Chapman Misunderstanding analysis of covariance J Abnorm Psychol 110 2001 40 48
89. Y.F. Tai, R. Hoshi, C.M. Brignell, L. Cohen, D.J. Brooks, and H.V. Curran et al. Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ("Ecstasy"): An 18F-dopa PET study Neuropsychopharmacology 36 2011 735 743
90. U.E. Busto, L. Redden, H. Mayberg, S. Kapur, S. Houle, and L.A. Zawertailo Dopaminergic activity in depressed smokers: A positron emission tomography study Synapse 63 2009 681 689
91. R.K. Salokangas, H. Vilkman, T. Ilonen, T. Taiminen, J. Bergman, and M. Haaparanta et al. High levels of dopamine activity in the basal ganglia of cigarette smokers Am J Psychiatry 157 2000 632 634
92. E.F. Domino, L. Ni, Y. Xu, R.A. Koeppe, S. Guthrie, and J.K. Zubieta Regional cerebral blood flow and plasma nicotine after smoking tobacco cigarettes Prog Neuropsychopharmacol Biol Psychiatry 28 2004 319 327